341 related articles for article (PubMed ID: 16011832)
1. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
[TBL] [Abstract][Full Text] [Related]
6. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
7. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates.
Hegde R; Borkow G; Berchanski A; Lapidot A
FEBS J; 2007 Dec; 274(24):6523-36. PubMed ID: 18028446
[TBL] [Abstract][Full Text] [Related]
8. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
Fujii N; Tamamura H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
Rosenkilde MM; Gerlach LO; Hatse S; Skerlj RT; Schols D; Bridger GJ; Schwartz TW
J Biol Chem; 2007 Sep; 282(37):27354-27365. PubMed ID: 17599916
[TBL] [Abstract][Full Text] [Related]
10. Cyclic zinc-dithiocarbamate-S,S'-dioxide blocks CXCR4-mediated HIV-1 infection.
Takamune N; Misumi S; Shoji S
Biochem Biophys Res Commun; 2000 Jun; 272(2):351-6. PubMed ID: 10833417
[TBL] [Abstract][Full Text] [Related]
11. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
12. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand.
Dong CZ; Kumar S; Choi WT; Madani N; Tian S; An J; Sodroski JG; Huang Z
J Med Chem; 2005 Dec; 48(25):7923-4. PubMed ID: 16335916
[TBL] [Abstract][Full Text] [Related]
13. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
Szabo I; Wetzel MA; Zhang N; Steele AD; Kaminsky DE; Chen C; Liu-Chen LY; Bednar F; Henderson EE; Howard OM; Oppenheim JJ; Rogers TJ
J Leukoc Biol; 2003 Dec; 74(6):1074-82. PubMed ID: 12972507
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists.
Iwasaki Y; Akari H; Murakami T; Kumakura S; Dewan MZ; Yanaka M; Yamamoto N
Cancer Sci; 2009 Apr; 100(4):778-81. PubMed ID: 19245436
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
16. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.
Howard OM; Oppenheim JJ; Hollingshead MG; Covey JM; Bigelow J; McCormack JJ; Buckheit RW; Clanton DJ; Turpin JA; Rice WG
J Med Chem; 1998 Jun; 41(13):2184-93. PubMed ID: 9632350
[TBL] [Abstract][Full Text] [Related]
18. SDF-1-induced activation of ERK enhances HIV-1 expression.
Montes M; Tagieva NE; Heveker N; Nahmias C; Baleux F; Trautmann A
Eur Cytokine Netw; 2000 Sep; 11(3):470-7. PubMed ID: 11022134
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles.
DeMarco SJ; Henze H; Lederer A; Moehle K; Mukherjee R; Romagnoli B; Robinson JA; Brianza F; Gombert FO; Lociuro S; Ludin C; Vrijbloed JW; Zumbrunn J; Obrecht JP; Obrecht D; Brondani V; Hamy F; Klimkait T
Bioorg Med Chem; 2006 Dec; 14(24):8396-404. PubMed ID: 17010618
[TBL] [Abstract][Full Text] [Related]
20. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Huskens D; Vermeire K; Profy AT; Schols D
Antiviral Res; 2009 Oct; 84(1):38-47. PubMed ID: 19664662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
